eIF3e Antibody (23GB5915)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-50439
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
Western Blot, Flow Cytometry
Label
Unconjugated
Antibody Source
Monoclonal Rabbit IgG Clone # 23GB5915
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
A synthesized peptide derived from human eIF3e (Uniprot: P60228)
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for eIF3e Antibody (23GB5915)
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS (pH 7.4), 50% glycerol
Preservative
0.02% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: eIF3e
Alternate Names
eIF-3 p48, eIF3e, eIF3-p48, EIF3S6EIF3-P48, Eukaryotic translation initiation factor 3 subunit 6, eukaryotic translation initiation factor 3 subunit E, eukaryotic translation initiation factor 3, subunit 6 (48kD), eukaryotic translation initiation factor 3, subunit 6 48kDa, eukaryotic translation initiation factor 3, subunit E, INT6eIF3-p46, mammary tumor-associated protein INT6, murine mammary tumor integration site 6 (oncogene homolog), Viral integration site protein INT-6 homolog
Gene Symbol
EIF3E
Additional eIF3e Products
Product Documents for eIF3e Antibody (23GB5915)
Product Specific Notices for eIF3e Antibody (23GB5915)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...